The 16th Annual Immunogenicity for Biotherapeutics 2015 provides an insight on the uncertainty surrounding immune response prediction and minimization, including strategies to overcome immunogenicity challenges from pre-clinical and development all the way through post-clinical stages.
Topics
- The risks of immunogenicity from concept to product - Strategies and case studies
- Technical and regulatory perspectives from senior FDA and industry experts
- Must-have features of molecular design to minimize or eliminate epitopes
- Transgenic animal models to get the best grasp on predicting immunogenicity
- Managing and reducing off-target toxicity concerns with antibody-drug conjugates and other protein therapeutics
- Newly-developed varieties of biomolecules, including biosimilars, nanomedicines, bispecifics and antibody-drug conjugates
- Higher-order structure techniques and assessment to improve the safety of therapeutic candidates
Who should Attend
Attendees from:
- Biologic Research
- Therapeutic Protein
- Immunochemistry
- Immunotherapeutics
- Immunology
- Protein Biochemistry
- Bioanalytical Method Development
- Immunoassays
- Antibody Engineering
- Drug safety
- Pharmacokinetics/ Pharmacodynamics
- Bioanalytical Research
- Assay Development
